Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Accumulated Expenses (2017 - 2025)

Puma Biotechnology's Other Accumulated Expenses history spans 9 years, with the latest figure at $209000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 88.29% year-over-year to $209000.0; the TTM value through Dec 2025 reached $209000.0, up 88.29%, while the annual FY2025 figure was $209000.0, 88.29% up from the prior year.
  • Other Accumulated Expenses reached $209000.0 in Q4 2025 per PBYI's latest filing, up from $182000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $733000.0 in Q2 2021 to a low of $81000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $352700.0, with a median of $290000.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 138.6% in 2023, then plummeted 78.36% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $632000.0 in 2021, then plummeted by 65.98% to $215000.0 in 2022, then soared by 138.6% to $513000.0 in 2023, then plummeted by 78.36% to $111000.0 in 2024, then surged by 88.29% to $209000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Other Accumulated Expenses are $209000.0 (Q4 2025), $182000.0 (Q3 2025), and $138000.0 (Q2 2025).